Abstract
Therapeutic options for metastatic melanoma have expanded dramatically over the past decade. Advances in tumor biology, immunotherapy, and adoptive cellular therapy are offering patients more options and requiring oncology advanced practitioners to develop familiarity with increasingly complex treatment modalities and care pathways. Speakers at JADPRO Live 2025 focused on extracutaneous melanoma—particularly mucosal and uveal melanoma—and highlighted novel immune-based therapies, including immune-mobilizing monoclonal T-cell receptors against cancer (ImmTACs) and tumor-infiltrating lymphocyte (TIL) therapy.
